Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US7575748B1 · kind B1 · utility
69Cited by
41References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 17, 2006 |
| Grant date | Aug 18, 2009 |
| Priority date | — |
| Expiry date | Jul 17, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.